Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors
1,874
edits
Changes
no edit summary
==Cancer Category/Type==
==Cancer Category/Type==
[[Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]]
[[HAEM4:Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]]
[[Acute Myeloid Leukemia (AML) with Mutated FLT3]]
[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
''FLT3'' mutations occur in about one-third of patients with AML [3]. In-frame duplications of 3 to >400 base pairs, also known as internal tandem duplications (ITDs), are the most common mutations in ''FLT3'' and they occur in up to 30% of adult patients with ''de novo'' AML [3,4,5,6]. About 70% of ''FLT3''-ITDs occur in the JMD and about 30% in the TKD [3]. The JMD inhibits activation of the receptor by steric hindrance, preventing the TKD from assuming an active conformation; presence of an ITD causes loss of this inhibitory effect, resulting in activation of the TKD.
''FLT3'' mutations occur in about one-third of patients with AML [3]. In-frame duplications of 3 to >400 base pairs, also known as internal tandem duplications (ITDs), are the most common mutations in ''FLT3'' and they occur in up to 30% of adult patients with ''de novo'' AML [3,4,5,6]. About 70% of ''FLT3''-ITDs occur in the JMD and about 30% in the TKD [3]. The JMD inhibits activation of the receptor by steric hindrance, preventing the TKD from assuming an active conformation; presence of an ITD causes loss of this inhibitory effect, resulting in activation of the TKD.
==Internal Pages==
==Internal Pages==
[[Acute Myeloid Leukemia (AML) with Mutated FLT3]]
[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
==External Links==
==External Links==